Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

1.6K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.6K
Recombinant DNA01:09

Recombinant DNA

101.5K
Overview
101.5K
Rab Proteins01:14

Rab Proteins

4.9K
Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
4.9K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.3K
Overview
83.3K
Immunological Memory01:23

Immunological Memory

14.9K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
14.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structures of Marburgvirus glycoprotein and its complex with NPC1 receptor.

Nature·2026
Same author

Omicron KP.3 RBD-Containing Spike mRNA Vaccine Induces Broadly Neutralizing Antibodies with Protection Against SARS-CoV-2 Omicron Infection in Mice.

Vaccines·2026
Same author

Modulation of Doxorubicin-Induced ROS Accumulation in Cardiomyocytes Using Ibuprofen-Conjugated Synthetic Lipids as Carriers.

ACS applied bio materials·2025
Same author

Glycosylated Receptor-Binding-Domain-Targeting Mucosal Vaccines Protect Against SARS-CoV-2 Omicron and MERS-CoV.

Vaccines·2025
Same author

Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

Imbalanced VWF-ADAMTS13 axis contributes to the detrimental impact of a preceding respiratory tract infection on stroke.

Blood advances·2025
Same journal

RETRACTED: Bakshi et al. Crocin Inhibits Angiogenesis and Metastasis in Colon Cancer via TNF-α/NF-kB/VEGF Pathways. <i>Cells</i> 2022, <i>11</i>, 1502.

Cells·2026
Same journal

Correction: Verde et al. Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses. <i>Cells</i> 2025, <i>14</i>, 680.

Cells·2026
Same journal

Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype.

Cells·2026
Same journal

IL-4/IL-13-Driven Dysregulation of Epidermal Lipid Metabolism in Atopic Dermatitis: An Immunometabolic Link Between Type 2 Inflammation and Barrier Dysfunction.

Cells·2026
Same journal

Activity of DNA- and RNA-Guided Prokaryotic Argonautes in Human Mitochondria.

Cells·2026
Same journal

Placental Pathophysiology in Maternal Psychoactive Substance Use: Biological, Clinical, and Forensic Perspectives.

Cells·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

3.0K

MERS-CoV RBD-mRNA Presents Better Immunogenicity and Protection than the Spike-mRNA.

Qian Liu1, Abhishek K Verma2, Xiaoqing Guan1

  • 1Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.

Cells
|December 10, 2025
PubMed
Summary
This summary is machine-generated.

The receptor-binding domain (RBD) mRNA vaccine demonstrated superior immunogenicity and protection against Middle East respiratory syndrome coronavirus (MERS-CoV) compared to the spike (S) mRNA vaccine in mice.

Keywords:
MERS-CoVcoronavirusneutralizing activityprotective efficacyreceptor-binding domainspike

More Related Videos

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.4K
Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

5.0K

Related Experiment Videos

Last Updated: Jan 9, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

3.0K
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.4K
Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

5.0K

Area of Science:

  • Virology
  • Immunology
  • Vaccine Development

Background:

  • Middle East respiratory syndrome coronavirus (MERS-CoV) poses a significant public health risk.
  • The MERS-CoV spike (S) protein, particularly its receptor-binding domain (RBD), is crucial for viral entry and a key target for vaccine development.
  • Direct comparative studies on the immunogenicity and efficacy of S- versus RBD-based MERS-CoV vaccines are lacking.

Purpose of the Study:

  • To compare the immunogenicity, neutralizing activity, and protective efficacy of two mRNA vaccines targeting either the S protein (S-mRNA) or the RBD (RBD-mRNA) of MERS-CoV.
  • To evaluate the durability of immune responses and protection conferred by these vaccines in a mouse model.

Main Methods:

  • Two lipid nanoparticle (LNP)-encapsulated mRNA vaccines, S-mRNA and RBD-mRNA, were developed and administered to mice.
  • Immunogenicity was assessed by measuring antibody titers and neutralizing activity against MERS-CoV strains and variants.
  • Protective efficacy was evaluated in a middle-aged mouse model challenged with MERS-CoV.

Main Results:

  • Both LNP-encapsulated mRNA vaccines exhibited stability across various temperatures.
  • RBD-mRNA elicited significantly higher and more durable antibody responses compared to S-mRNA.
  • RBD-mRNA demonstrated stronger and broader neutralizing activity against MERS-CoV and its variants, and provided durable protection against infection in mice.

Conclusions:

  • LNP-encapsulated RBD-mRNA is a highly effective vaccine candidate against MERS-CoV.
  • The RBD-mRNA vaccine shows significant potential for further development due to its superior immunogenicity, neutralizing capacity, and protective efficacy.